

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/729,387
Filing Date	December 3, 2003
First Named Inventor	Francis T. GILES
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	STROMIX-007

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
Cm		5,041,449		Belleau et al	08/20/1991	
		5,817,667		Chu et al	10/06/1998	
		5,270,315		Belleau et al	12/14/1993	
		6,350,753		Belleau et al.	2/26/2002	
		6,645,972		Jolivet et al.	11/11/2003	
		6,747,036		Gordeau et al.	6/8/2004	
		2003/0013660		Attardo et al.	1/16/2003	
		2003/0083316		Giles et al.	5/1/2003	
		2003/0027799		Jolivet	2/6/2003	
		2004/0192654		Gourdeau et al.	9/30/2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
Cm		WO	9607413			03/14/1996		
		EP	0337713			10/18/1995		
		WO	02/30922			04/18/2002		
		WO	02/076472			10/03/2002		
		WO	02/078678			10/10/2002		
		WO	03/037344			5/8/2003		

Examiner
Signature

Cm

Date
Considered

3-20-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark if the English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/729,387
		Filing Date	December 3, 2003
		First Named Inventor	Francis T. GILES
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	STROMIX-0007
Sheet	2	of	2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm		"FDA Approves Gleevec for Leukemia Treatment" FDA Consumer, US Dept. of Health, Educ. And Welfare, Public Health Services, US, vol. 4, July 2001, pg. 6, XP001145627	
cm		Giles F. et al. "Phase II Study of Troxatyl in Patients with Chronic Myeloid Leukemia in Blastic Phase (CML-BP)" Blood, W.B. Saunders Company, Orlando, FL, US, vol. 98, no. 11, part 2, (2001), pg. 2588, XP009007253	
cm		B. Scappini et al, "In vitro effects of ST1571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells", 2002 American Cancer Society, May 15 94(10):2653-62	
		R. Nimmanapalli et al, "Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias", Curr Opin. Oncol. 2002 Nov; 14(6):616-620	
		A. Hochhaus et al, "Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy", Leukemia 2002 Nov, 16(11):2190-6	
		M. Beran et al, "Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase", Cancer Res. 1993 Aug 1;53(15):3603-10	
		B. Kasper et al, "Favorable therapeutic index of a p210 BCR-ABL specific tyrosine kinase inhibitor: activity on lineage-committed and primitive chronic myelogenous leukaemia progenitors", Cancer Chemother Pharmacol (1999) 44:433-438	
		C.L. Sawyers, "Chronic myeloid leukemia" The New England Journal of Medicine, 1999; 340:1330-1340	
		B. J. Druker et al, "Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia", Blood 1999; 94(Suppl. 1):368a	
cm		Giles F. J. et al., "Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia", Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. United States, February 1, 2001, Vol. 19, No. 3, pp. 762-771, XP009007304	
		"Gleevec (STI-571) for chronic myeloid leukemia", Medical Letter on Drugs and Therapeutics, New Rochelle, NY, US, June 11, 2001, Vol. 43, No. 1106, pp. 49-50, XP001036570	
		M. Kotecki et al, "Isolation and characterization of a near-haploid human cell line", Exp Cell Res. 1999 Nov 1;252(2):273-80	
		A. Klejman et al, "Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI-571", Oncogene 2002, Aug 29; 21(31):5868-76	
		BS Andersson et al, "KBM-7 a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts", Leukemia 1995 Dec; 9(12):2100-8	
		J. Toplay et al, "Synergistic activity of the new ABL-specific tyrosine kinase inhibitor ST1571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells", Leukemia (2001) 15:342-347	

Examiner Signature		Date Considered	3-20-05
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
Application Number		10/729,387	
Filing Date		December 8, 2003	
First Named Inventor		Francis T. GILES	
Group Art Unit		1614	
Examiner Name		Unassigned	
Attorney Docket Number		PHARMA-139	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm		Orsolic, Nada et al. "Troxatyl and ST1571 Combination Therapy for Chronic Myeloid Leukemia: Preclinical In Vitro and In Vivo Evaluation", Blood, vol. 100, no. 11, (2002), Abstract No. 3107, XP0009027132	
		"FDA Approves Gleevec for Leukemia Treatment" FDA Consumer, US Dept. of Health, Educ. And Welfare, Public Health Services, US, vol. 4, July 2001, pg. 6, XP001145627	
cm		Giles F. et al. "Phase II Study of Troxatyl in Patients with Chronic Myeloid Leukemia in Blastoid Phase (CML-BP)" Blood, W.B. Saunders Company, Orlando, FL, US, vol. 98, no. 11, part 2, (2001), pg. 258B, XP009007253	

Examiner Signature	cm	Date Considered	3-20-05
-----------------------	----	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.